{"nct_id":"NCT05406401","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2024-10","start_date":"2022-07-14","start_date_type":"ACTUAL","primary_completion_date":"2029-04-26","primary_completion_date_type":"ESTIMATED","completion_date":"2029-04-26","completion_date_type":"ESTIMATED","phases":["PHASE2"],"tickers":["MRK"]}